A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Name: A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)
Published: 2026
License: Public Domain

Medical University of South Carolina · 2026

ClinicalTrials.gov · Datasets · License: Public Domain · 2026

Open Source ↗

triple-negative-breast-cancer

triple negative breast cancer (tnbc), elevated tumor-infiltrating lymphocytes, triple negative breast cancer, neoadjuvant chemoimmunotherapy, neoadjuvant treatment, tils, til, anthracycline sparing, non-anthracycline based, interventional, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs)

Related documents